ReviewThe Journal of nutrition2010
Equol: pharmacokinetics and biological actions.
Review in The Journal of nutrition, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 105 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
105 citing papers in PubMed, 3 syntheses or guidelines pooled it, 208 citations in OpenAlex.
- Can soy isoflavones in combination with soy protein change serum levels of C-reactive protein among patients with chronic inflammatory diseases? A systematic review and meta-analysis on randomized controlled trials.Journal of health, population, and nutrition · 2025Pooled it
- Pooled it
- Effects of soy isoflavones on cognitive function: a systematic review and meta-analysis of randomized controlled trials.Nutrition reviews · 2020Pooled it
- Soy food intake associates with changes in the metabolome and reduced blood pressure in a gut microbiota dependent manner.Nutrition, metabolism, and cardiovascular diseases : NMCD · 2020Trial
- Research protocol: effect of natural S-equol on blood pressure and vascular function--a six-month randomized controlled trial among equol non-producers of postmenopausal women with prehypertension or untreated stage 1 hypertension.BMC complementary and alternative medicine · 2016Trial
- Impact of dose, frequency of administration, and equol production on efficacy of isoflavones for menopausal hot flashes: a pilot randomized trial.Menopause (New York, N.Y.) · 2013Trial
- Estrogen receptor and PI3K/Akt signaling pathway involvement in S-(-)equol-induced activation of Nrf2/ARE in endothelial cells.PloS one · 2013Trial
- Long-term soy isoflavone supplementation and cognition in women: a randomized, controlled trial.Neurology · 2012Trial
- Equol production changes over time in postmenopausal women.The Journal of nutritional biochemistry · 2012Trial
- Equol production changes over time in pre-menopausal women.The British journal of nutrition · 2012Trial
- Soy isoflavone phase II metabolism differs between rodents and humans: implications for the effect on breast cancer risk.The American journal of clinical nutrition · 2011Trial
- Review
- Plant-Derived Foods and Medicines as Modulators of the Gut Microbiome: Molecular Interactions and Implications for Disease and Therapy.Molecules (Basel, Switzerland) · 2026Review
- Effect of Diets Containing Phytoestrogen on Livestock Production: Nutrient Utilization, Carcass Traits, Lactational Performance, and Reproductive Function-A Review.Molecules (Basel, Switzerland) · 2026Review
- Soy and the gut microbiome: a bi-directional relationship shaping nutrition and health.European journal of nutrition · 2026Review
- Precision nutrition in Asian populations: a Multi-omics review of mechanisms, biomarkers, and implementation pathways.Journal of nutritional science · 2026Review
- Phytochemicals: Principles and Practice.Biology · 2025Review
- Review
- Pharmacotherapeutic potential of daidzein: insights into mechanisms and clinical relevance.Inflammopharmacology · 2025Review
- Bioactives for Estrogen-Deficient Skin: Topical and Oral Supplement Clinical Studies. A Narrative Review.Dermatology and therapy · 2025Review
45 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
Equol [7-hydroxy-3-(4'-hydroxyphenyl)-chroman], an isoflavan produced by intestinal bacteria in response to soy isoflavone intake in some but not all humans, exhibits a wide range of biological properties. It exists as the diastereoisomers S-(-)equol and R-(+)equol. Intestinal bacteria produce exclusively S-(-)equol, which has selective affinity for estrogen receptor (ER)-beta. The evidence is conflicting on whether there is an advantage to producing S-(-)equol in response to soy isoflavone intakes, but the ability to now synthesize these diastereoisomers opens the way for future clinical trials to directly examine their potential in a number of hormone-dependent conditions. In this review, the plasma and urinary pharmacokinetics of S-(-)equol and R-(+)equol are reviewed and summarized, and some of the more recent evidence supporting potential biological effects of S-(-)equol is considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.